These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 7295098

  • 1. Potential role of middle molecular compounds in the development of uremic anemia.
    Leber HW, Debus E, Grulich U, Schütterle G.
    Artif Organs; 1981; 4 Suppl():63-7. PubMed ID: 7295098
    [Abstract] [Full Text] [Related]

  • 2. Influence of middle molecules on the anemia of uremic patients.
    Leber HW, Spiegelhalter R, Ulm A, Goubeaud G, Rawer P.
    Artif Organs; 1978 Nov; 2(4):378-81. PubMed ID: 743010
    [Abstract] [Full Text] [Related]

  • 3. Oxidative stress and delta-ALA-D activity in chronic renal failure patients.
    da Silva AC, Rocha JB, Morsch AL, Zanin RF, Kaizer R, Maldonado PA, Arantes LC, Silva LA, Morsch VM, Schetinger MR.
    Biomed Pharmacother; 2007 Nov; 61(2-3):180-5. PubMed ID: 17383846
    [Abstract] [Full Text] [Related]

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity?
    Vanholder R, Van Laecke S, Glorieux G.
    J Nephrol; 2008 Nov; 21(2):146-60. PubMed ID: 18446708
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Erythrocyte susceptibility to oxidative stress in chronic renal failure patients under different substitutive treatments.
    Lucchi L, Bergamini S, Iannone A, Perrone S, Stipo L, Olmeda F, Caruso F, Tomasi A, Albertazzi A.
    Artif Organs; 2005 Jan; 29(1):67-72. PubMed ID: 15644086
    [Abstract] [Full Text] [Related]

  • 12. Evidence that the anemia of renal failure participates in overall uremic toxicity.
    Kokot F, Wiecek A.
    Kidney Int Suppl; 1997 Nov; 62():S83-6. PubMed ID: 9350689
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Uremic toxins].
    Vanholder R.
    Nephrologie; 2003 Nov; 24(7):373-6. PubMed ID: 14650749
    [Abstract] [Full Text] [Related]

  • 16. Biochemical and clinical evidence for uremic toxicity.
    Bouré T, Vanholder R.
    Artif Organs; 2004 Mar; 28(3):248-53. PubMed ID: 15046622
    [Abstract] [Full Text] [Related]

  • 17. Effect of haemodialysate and its peptide fractions on acetylcholinesterase activity in erythrocytes from healthy subjects and patients with terminal renal failure.
    Smoleński O, Tabarowski Z, Miszta H, Dabrowski Z.
    Int Urol Nephrol; 1993 Mar; 25(5):503-8. PubMed ID: 8270380
    [Abstract] [Full Text] [Related]

  • 18. [Middle-molecular uremic toxins (review of the literature)].
    Tupikova ZA.
    Vopr Med Khim; 1983 Mar; 29(1):2-10. PubMed ID: 6340339
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Loss of phospholipids asymmetry in red blood cells contributes to anemia in uremic patients.
    Kong QY, Wu X, Li J, Peng WX, Ye R, Lindholm B, Wang T.
    Adv Perit Dial; 2001 Mar; 17():58-60. PubMed ID: 11510298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.